Literature DB >> 19809965

["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept].

U Müller-Ladner1, R Alten, A Heiligenhaus, J Kekow, S Koletzko, U Mrowietz, T Ochsenkühn, M Radke, K Reich, M Rudwaleit, S Schreiber.   

Abstract

The pro-inflammatory cytokine TNF alpha (TNF) has a key position in the pathogenesis of various infectious and inflammatory diseases. Clarification of its pivotal role in the pathogenesis of rheumatoid arthritis, spondyloarthritis, uveitis, psoriasis and inflammatory bowel disease has resulted in the successful development of TNF- blocking therapies, which have disease-modifying properties that exceed the effects of conventional therapeutic options. For this reason data on the concurrence of several chronic inflammatory diseases have led to the hypothesis of common pathogenetic processes of cytokine dysregulation. The acronym TRECID describes this concept of "TNF RElated Chronic Inflammatory Diseases". Physicians of different specialties have integrated new therapeutic options with TNF-blocking therapies into their strategies for the management of the affected patients. Thus the concept of TRECID can be regarded as a role model for a dynamic, interdisciplinary cooperation based on shared pathophysiological aspects. Copyright Georg Thieme Verlag KG Stuttgart . New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809965     DOI: 10.1055/s-0029-1242011

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  6 in total

Review 1.  [Brief review of the diagnostics of pyoderma gangraenosum].

Authors:  Joachim Dissemond
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

2.  Ulcerated necrobiosis lipoidica as a rare cause for chronic leg ulcers: case report series of ten patients.

Authors:  Cindy Franklin; Maren Stoffels-Weindorf; Uwe Hillen; Joachim Dissemond
Journal:  Int Wound J       Date:  2013-10-07       Impact factor: 3.315

3.  Patients with pyoderma gangrenosum - analyses of the German DRG data from 2012.

Authors:  Finja Jockenhöfer; Joachim Klode; Knut Kröger; Alexander Roesch; Philipp Al Ghazal; Joachim Dissemond
Journal:  Int Wound J       Date:  2015-08-06       Impact factor: 3.315

Review 4.  Pyoderma gangrenosum: pathogenetic oriented treatment approaches.

Authors:  Uwe Wollina; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2014-06-05

5.  Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.

Authors:  Tara L Spivey; Lorenzo Uccellini; Maria Libera Ascierto; Gabriele Zoppoli; Valeria De Giorgi; Lucia Gemma Delogu; Alyson M Engle; Jaime M Thomas; Ena Wang; Francesco M Marincola; Davide Bedognetti
Journal:  J Transl Med       Date:  2011-10-12       Impact factor: 5.531

6.  Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients.

Authors:  Philipp Al Ghazal; Katharina Herberger; Jörg Schaller; Anke Strölin; Norman-Philipp Hoff; Tobias Goerge; Hannelore Roth; Eberhard Rabe; Sigrid Karrer; Regina Renner; Jan Maschke; Thomas Horn; Julia Hepp; Sabine Eming; Uwe Wollina; Markus Zutt; Isabell Sick; Benno Splieth; Dorothea Dill; Joachim Klode; Joachim Dissemond
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.